Drugs & Side Effects | COX-2 / Arthritis

Vioxx News

Fourth Vioxx Lawsuit Sent to Jury; Merck Continues Strong Defense

RSS News Feeds
Drugs & Pharmacuticals
Stroke
Vioxx
 All RSS Feeds

At a glance:

The fourth Vioxx personal injury lawsuit has been handed to a jury for deliberation. With one loss and two wins in prior cases, Merck's stock is holding steady as they defend themselves against claims that they hid bad side effects and an increase in heart attack risks from patients prescribed the medication for arthritis and other painful conditions.
Although there is evidence that Merck hid information about increased incidences in heart attacks, their defense based on the timeframe in which plaintiffs took the drugs and other risk factors displayed by plaintiffs appears to be effective.

Jury to Start Deliberation in Two Vioxx Injury Cases

New York Times - 4/4/2006 1:23 AM

After a month of testimony, the fourth Vioxx-related personal injury trial ended Monday with well-worn closing arguments from lawyers for Merck and for two men who say the company's drug Vioxx caused their heart attacks.
 
Less than two years after Merck withdrew Vioxx from the market, and eight months after the first Vioxx case reached a verdict, litigation over the drug has settled into someth
 
· Read The Full Vioxx Article From New York Times -->

· Read All Vioxx (Rofecoxib) News Stories -->

Comments On Vioxx News Articles:


No Current Comments
Posted by Admin on 3/20/2006

There are no current comments. Why not post one?

Leave a Comment:

Once you click the 'Save Comment' button, you will receive a verification email from our website. Be sure to change any spam settings to allow webmaster@lawsuitsearch.com as a trusted sender.
 
If you are already a member, you can Sign In Here.
 
You can create your own FREE user account that you can use to participate in our message boards, blogs, newsletters and other community activities such as this one. To get your FREE user account, click here.

Email Address:

Your Name:

Message Title:

Message: